Personal Cfo Solutions, LLC Alkermes Plc. Transaction History

Personal Cfo Solutions, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$26.4 - $32.56 $2,402 - $2,962	91 Added 0.57%	16,091 $435,000
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $163 - $191	-6 Reduced 0.04%	16,000 $448,000
Q2 2023 Aug 10, 2023	SELL	$28.34 - $33.63 $396,589 - $470,618	-13,994 Reduced 46.65%	16,006 $500,000
Q1 2023 May 09, 2023	SELL	$25.31 - $29.02 $253,251 - $290,374	-10,006 Reduced 25.01%	30,000 $845,000
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $441,520 - $528,053	-20,124 Reduced 33.47%	40,006 $1.05 Million
Q3 2022 Nov 01, 2022	BUY	$22.0 - $31.87 $1.13 Million - $1.64 Million	51,524 Added 598.7%	60,130 $1.34 Million
Q2 2022 Aug 05, 2022	BUY	$26.4 - $30.54 $158 - $183	6 Added 0.07%	8,606 $256,000
Q4 2021 Feb 11, 2022	BUY	$21.47 - $32.08 $184,642 - $275,888	8,600 New	8,600 $200,000

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.55B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Personal Cfo Solutions, LLC with notifications on news.